Do you have a refractory patient not responding to medication?
Imagine a safe and effective treatment for anxiety, insomnia, and pain
… all in one simple-to-use device
without the side effects of pain and psychiatric medication
Alpha-Stim is the most researched medical device in its class and the most widely used and recommended cranial electrotherapy stimulator in the world.
What is Alpha-Stim?
Alpha-Stim is a state-of-the art prescription medical technology for the treatment of anxiety, insomnia and pain. Alpha-Stim utilizes a patented microcurrent waveform for unparalleled performance and safety.
Depending on the indication, a very mild electrical current is either applied with earclip electrodes to the head (a method called Cranial Electrotherapy Stimulation) or directly to the muscle and/or joint with hand-held probes or self-adhesive electrodes (a method called Microcurrent Electrical Therapy). Both treatments are well tolerated and safe.
The Alpha-Stim Advantage
- Low incidence of adverse effects.
- More efficacious than most other forms of therapy.
- Relatively easy to learn.
- Alternative in cases refractory to conventional care.
- Reduces or eliminates need for addictive medications.
- May be applied on schedule or PRN.
- May be self-administered by patients.
- Cumulative timer.
- Stand-alone or adjunct therapy.
Alpha-Stim in Your Practice
Alpha-Stim is FDA-cleared to treat anxiety, insomnia and pain. Consequently, this unique technology can easily be incorporated into your practice, providing you with an effective treatment choice for your patients. Learn more how Alpha-Stim can complement your practice.
Alpha-Stim vs. Medication
Alpha-Stim is a non-drug therapy with very mild, self-limiting side effects and as such it is much safer to use than drugs. In contrast to many psychoactive medications, there is no black box warning, or the potential for abuse or overdose with Alpha-Stim.
In contrast to pain, anti-anxiety or sleep drugs, many of which are addictive, there have never been any reports of addiction to electrical stimulation. Alpha-Stim is a safe, non-habit forming alternative to drugs to treat anxiety, insomnia and pain in patients with history of addiction.
Some classes of medications, including antidepressants may induce significant weight gain in patients taking the medication long-term or even short-term. No such side effects have ever been reported with Alpha-Stim.
A decreased production of saliva and xerostomia are among a slew of physical symptoms that are frequently associated with antidepressant use. No such side effects have ever been reported with Alpha-Stim treatments.
Most patients who take antidepressants such as SSRIs report various types of sexual dysfunction, and in some patients medication use may lead to sexual dysfunction that persists even after discontinuing the drug. Since Alpha-Stim in a non-drug treatment, it has absolutely no negative effects on sexual function.
While habituation and tolerance are common problems in medication use, no similar effects have been reported with Alpha-Stim treatments. In fact, as the benefits of Alpha-Stim accumulate with repeated use, most patients use their devices less over time.
Recent Publications
See a Complete list of Alpha-Stim Research
Results of the current [GAD] study demonstrate a significant improvement with CES, with a decrease in HARS score similar to that found in clinical trials with antidepressant and anxiolytic medicationsBystritsky et al. (2008). Journal of Clinical Psychiatry February 6, 2008: e1-e6- Developer
The large effect sizes for the effects of CES on anxiety and comorbid depression reveal a favorable risk/reward ratio supporting the use of CES for the treatment of anxiety and comorbid depression in evidence-based practice.Barclay & Barclay (2014). Journal of Affective Disorders 164:171-177- Developer
The large effect sizes for the effects of CES on anxiety and comorbid depression reveal a favorable risk/reward ratio supporting the use of CES for the treatment of anxiety and comorbid depression in evidence-based practice.
Barclay & Barclay (2014). Journal of Affective Disorders 164:171-177- Developer